iTeos Therapeutics, Inc.: M&A transaction — iTeos Therapeutics acquired by Concentra Biosciences for $10.047/sh plus CVR

iTeos Therapeutics, Inc.

Tender offer closed with 72.17% of shares tendered; all conditions satisfied; merger effective Aug 29, 2025.
Shareholders receive $10.047 cash per share plus one non-transferable CVR per share.
CVR entitles holders to 80% of net proceeds from future disposition of specific product candidates (EOS-984, EOS-215, PTPN1/2 program) within 6-month disposition period.
Board resigned; new directors/officers from Concentra (Kevin Tang CEO, Michael Hearne CFO, etc.).
Company requests delisting from Nasdaq and intends to deregister with SEC.

item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

iTeos Therapeutics, Inc.: Bylaws amended and restated in their entirety.

Change: bylaw amendment

Exact text from the filing

the Company's certificate of incorporation and bylaws were amended and restated in their entirety

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

iTeos Therapeutics, Inc.: Certificate of incorporation amended and restated in its entirety.

Change: charter amendment

Exact text from the filing

the Company's certificate of incorporation and bylaws were amended and restated in their entirety

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.99

iTeos Therapeutics, Inc. underwent a change of control involving Concentra Biosciences, LLC for $10.047 in cash per Share plus one non-transferable contractual contingent value right per Share (closed 2025-08-29).

Action: change of control
Counterparty: Concentra Biosciences, LLC
Consideration: $10.047 in cash per Share plus one non-transferable contractual contingent value right per Share
Closing: 2025-08-29

Exact text from the filing

(the “Company”) in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 21, 2025, the Company entered into an Agreement and Plan of Merger, dated as of July 18, 2025 (the “Merger Agreement”) with Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), and Concentra Merger Sub VIII, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-25-192031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.